Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18930230 | 1.00 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18930599 | 0.88 | CTSS (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21144822 | 0.88 | CTSS (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5945619 | 0.88 | KLK5 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5945647 | 0.87 | KLK5 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7629197 | 0.85 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7629200 | 0.85 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21144772 | 0.83 | REN (0.41) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL21144769 | 0.83 | REN (0.41) | RENCTSSCTSKCTSLCTSB | |
| SCHEMBL21144931 | 0.83 | REN (0.41) | RENCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | PSEN1 3111/4885PSEN2 2514/4885APH1B 1555/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | PSEN1 3111/4885PSEN2 2514/4885APH1B 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.